$ATMV
AlphaVest Acquisition Corp.

2023 Q4 Form 10-Q Financial Statement

#000149315223039320 Filed on November 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $189.1K $200.0K $3.750K
YoY Change 145.42% 5233.33%
Operating Profit -$198.8K
YoY Change
Interest Expense $987.9K $950.0K
YoY Change 2483.99%
% of Operating Profit
Other Income/Expense, Net $3.871K
YoY Change
Pretax Income $798.7K $760.0K -$3.750K
YoY Change -2156.99% -20366.67%
Income Tax
% Of Pretax Income
Net Earnings $798.7K $756.0K -$3.750K
YoY Change -2156.99% -20259.68%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.19 $0.08 $0.00
COMMON SHARES
Basic Shares Outstanding 9.181M shares 9.181M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.56K $60.00K $0.00
YoY Change -95.67%
Cash & Equivalents $28.56K $57.84K
Short-Term Investments
Other Short-Term Assets $34.57K $50.00K $355.9K
YoY Change -58.23% -85.95%
Inventory
Prepaid Expenses $34.57K $47.62K
Receivables
Other Receivables
Total Short-Term Assets $63.13K $105.5K $357.7K
YoY Change -91.49% -70.51%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $50.88M $73.01M
YoY Change -27.75%
Other Assets $0.00
YoY Change
Total Long-Term Assets $50.88M $73.01M $0.00
YoY Change -27.78%
TOTAL ASSETS
Total Short-Term Assets $63.13K $105.5K $357.7K
Total Long-Term Assets $50.88M $73.01M $0.00
Total Assets $50.94M $73.12M $357.7K
YoY Change -28.44% 20343.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $213.1K $70.00K $67.48K
YoY Change -14.07% 3.73%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $165.0K $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $388.0K $76.17K $334.7K
YoY Change 50.45% -77.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $388.0K $76.17K $334.7K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $380.0K $80.00K $334.7K
YoY Change 47.34% -76.09%
SHAREHOLDERS EQUITY
Retained Earnings -$325.1K $29.07K
YoY Change 663.42%
Common Stock $228.00 $228.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$324.8K $29.30K $23.00K
YoY Change
Total Liabilities & Shareholders Equity $50.94M $73.12M $357.7K
YoY Change -28.44% 20343.49%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income $798.7K $756.0K -$3.750K
YoY Change -2156.99% -20259.68%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$30.48K -$160.0K $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $23.12M
YoY Change -132.85%
Cash From Investing Activities $23.12M
YoY Change -132.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -23.12M
YoY Change -132.54%
NET CHANGE
Cash From Operating Activities -30.48K -160.0K 0.000
Cash From Investing Activities 23.12M
Cash From Financing Activities -23.12M
Net Change In Cash -30.48K -160.0K 0.000
YoY Change -104.62%
FREE CASH FLOW
Cash From Operating Activities -$30.48K -$160.0K $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001937891
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
usd
CY2022Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
usd
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
usd
us-gaap Interest Income Other
InterestIncomeOther
usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
usd
us-gaap Increase Decrease In Marketable Securities Restricted
IncreaseDecreaseInMarketableSecuritiesRestricted
usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
ATMV Accretion For Common Stock Subject To Redemption Amount
AccretionForCommonStockSubjectToRedemptionAmount
usd
ATMV Deferred Offering Costs Paid By Sponsor In Exchange For Issuance Of Common Stock
DeferredOfferingCostsPaidBySponsorInExchangeForIssuanceOfCommonStock
usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41574
dei Entity Registrant Name
EntityRegistrantName
ALPHAVEST ACQUISITION CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Address Address Line1
EntityAddressAddressLine1
420 Lexington Ave
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2446
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10170
dei City Area Code
CityAreaCode
203
dei Local Phone Number
LocalPhoneNumber
998-5540
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9180500 shares
CY2023Q3 us-gaap Cash
Cash
57843 usd
CY2022Q4 us-gaap Cash
Cash
659035 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
47621 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
82771 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
105464 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
741806 usd
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
32380 usd
CY2023Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
73010689 usd
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
70418228 usd
CY2023Q3 us-gaap Assets
Assets
73116153 usd
CY2022Q4 us-gaap Assets
Assets
71192414 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
66331 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
248034 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9837 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9837 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
76168 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
257871 usd
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
6900000 shares
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
6900000 shares
CY2023Q3 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.58
CY2022Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.20
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
73010689 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
70380000 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2280500 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2280500 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2280500 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2280500 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
228 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
228 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
596893 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
29068 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42578 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
29296 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
554543 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73116153 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71192414 usd
CY2023Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
198821 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
487194 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3749 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-198821 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-487194 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3749 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
954788 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2592461 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
21 usd
us-gaap Interest Income Other
InterestIncomeOther
175 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
954809 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2592636 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
755988 usd
us-gaap Net Income Loss
NetIncomeLoss
2105442 usd
us-gaap Net Income Loss
NetIncomeLoss
-3749 usd
us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
225000 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
554543 usd
CY2023Q1 ATMV Stock Issued During Period Value For Common Stock Subject To Redemption Amount
StockIssuedDuringPeriodValueForCommonStockSubjectToRedemptionAmount
-841220 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
644898 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
358221 usd
CY2023Q2 ATMV Stock Issued During Period Value For Common Stock Subject To Redemption Amount
StockIssuedDuringPeriodValueForCommonStockSubjectToRedemptionAmount
-834681 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
704556 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
228096 usd
CY2023Q3 ATMV Stock Issued During Period Value For Common Stock Subject To Redemption Amount
StockIssuedDuringPeriodValueForCommonStockSubjectToRedemptionAmount
-954788 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
755988 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
29296 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3749 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3749 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
21251 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
21251 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
21251 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
21251 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
21251 usd
us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
225000 shares
us-gaap Net Income Loss
NetIncomeLoss
2105442 usd
us-gaap Net Income Loss
NetIncomeLoss
-3749 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-67530 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-356164 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-181703 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
67740 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
292173 usd
us-gaap Increase Decrease In Marketable Securities Restricted
IncreaseDecreaseInMarketableSecuritiesRestricted
2592461 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-601192 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-601192 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
659035 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57843 usd
ATMV Accretion For Common Stock Subject To Redemption Amount
AccretionForCommonStockSubjectToRedemptionAmount
2630689 usd
ATMV Deferred Offering Costs Paid By Sponsor In Exchange For Issuance Of Common Stock
DeferredOfferingCostsPaidBySponsorInExchangeForIssuanceOfCommonStock
25000 usd
CY2022Q4 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
61200000 usd
CY2022Q4 ATMV Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.20
CY2022Q4 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
1725000 usd
ATMV Percentage Of Cash Fee On Consideration Payable In Initial Business Combination
PercentageOfCashFeeOnConsiderationPayableInInitialBusinessCombination
0.010 pure
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-3734629 usd
ATMV Underwriting Expenses
UnderwritingExpenses
1725000 usd
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
629929 usd
CY2023Q3 us-gaap Assets Held In Trust
AssetsHeldInTrust
1425000 usd
ATMV Condition For Future Business Combination Use Of Proceeds Percentage
ConditionForFutureBusinessCombinationUseOfProceedsPercentage
0.80 pure
ATMV Condition For Future Business Combination Threshold Percentage Ownership
ConditionForFutureBusinessCombinationThresholdPercentageOwnership
0.50 pure
CY2023Q3 us-gaap Minimum Net Worth Required For Compliance
MinimumNetWorthRequiredForCompliance
5000001 usd
CY2023Q3 us-gaap Minimum Net Worth Required For Compliance
MinimumNetWorthRequiredForCompliance
5000001 usd
ATMV Percentage Of Public Shares That Would Not Be Redeemed If Business Combination Is Not Completed Within Initial Combination Period
PercentageOfPublicSharesThatWouldNotBeRedeemedIfBusinessCombinationIsNotCompletedWithinInitialCombinationPeriod
1 pure
ATMV Percentage Of Public Shares That Would Not Be Redeemed If Business Combination Is Not Completed Within Initial Combination Period
PercentageOfPublicSharesThatWouldNotBeRedeemedIfBusinessCombinationIsNotCompletedWithinInitialCombinationPeriod
1 pure
CY2023Q3 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000 usd
CY2023Q3 ATMV Value Per Share To Be Maintained In The Trust Account
ValuePerShareToBeMaintainedInTheTrustAccount
10.20
CY2023Q3 us-gaap Cash
Cash
57843 usd
CY2023Q3 ATMV Working Capital
WorkingCapital
29296 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zDfFl0kxdJ9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zMOICDc2oPRg">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statement in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57843 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
659035 usd
CY2023Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
73010689 usd
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
70418228 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
954788 usd
CY2023Q3 ATMV Offering Costs
OfferingCosts
3734630 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
73305000 usd
ATMV Cash To Operating Account
CashToOperatingAccount
657285 usd
ATMV Underwriting Expenses
UnderwritingExpenses
1725000 usd
ATMV Other Offering Expenses
OtherOfferingExpenses
263675 usd
ATMV Amount Held Back For Sponsor Portion Of Risk Capital
AmountHeldBackForSponsorPortionOfRiskCapital
279040 usd
ATMV Adjustments To Reconcile Offering Proceeds To Ordinary Shares To Possible Redemption
AdjustmentsToReconcileOfferingProceedsToOrdinarySharesToPossibleRedemption
2925000 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
70380000 usd
CY2023Q1 ATMV Stock Issued During Period Value For Common Stock Subject To Redemptions Amount
StockIssuedDuringPeriodValueForCommonStockSubjectToRedemptionsAmount
841220 usd
CY2023Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
71221220 usd
CY2023Q2 ATMV Stock Issued During Period Value For Common Stock Subject To Redemptions Amount
StockIssuedDuringPeriodValueForCommonStockSubjectToRedemptionsAmount
834681 usd
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
72055901 usd
CY2023Q3 ATMV Stock Issued During Period Value For Common Stock Subject To Redemptions Amount
StockIssuedDuringPeriodValueForCommonStockSubjectToRedemptionsAmount
954788 usd
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
73010689 usd
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2280500 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2280500 shares
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
6900000 shares
CY2023Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
30000 usd
CY2023Q3 us-gaap Other Expenses
OtherExpenses
3871 usd
us-gaap Professional Fees
ProfessionalFees
0 usd
CY2022Q2 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
150000 usd
CY2023Q1 us-gaap Other Comprehensive Income Defined Benefit Plan Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
784 usd
CY2023Q3 us-gaap Other Comprehensive Income Defined Benefit Plan Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
198 usd
us-gaap Other Comprehensive Income Defined Benefit Plan Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
0 usd

Files In Submission

Name View Source Status
0001493152-23-039320-index-headers.html Edgar Link pending
0001493152-23-039320-index.html Edgar Link pending
0001493152-23-039320.txt Edgar Link pending
0001493152-23-039320-xbrl.zip Edgar Link pending
atmv-20230930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
atmv-20230930_cal.xml Edgar Link unprocessable
atmv-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atmv-20230930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
Show.js Edgar Link pending
atmv-20230930_lab.xml Edgar Link unprocessable